Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

About the trial

Sponsor

AbbVie

Tested

Placebo for Navitoclax (drug), Ruxolitinib (drug), Navitoclax (drug)

Dates

Started 2020-09-29; completion 2025-01-29

Results posted

Yes

Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in assessment of change in spleen volume when compared to ruxolitinib in participants with myelofibrosis. Navitoclax is an investigational drug for the treatment of myelofibrosis. Participants in this study are…

From ClinicalTrials.gov, last updated 2026-03-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $167,755 in research payments for this study in 2025 (46 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.